The trials, the rulings and the studies that actually affect you, summarised for a busy woman and linked to the original source. No hype. No diet talk. Just what changed and what it means for you.
A study of 60,000 patients found that about 40% stopped their GLP-1 within a year, but most started again soon after: 42% within a year, nearly 60% within two. The weight tends to come back, and so do they.
The FDA has proposed formally barring pharmacies from making compounded copies of semaglutide, tirzepatide and liraglutide. It is the end of the cheaper, copied versions that filled the shortage years.
New research links GLP-1 use to a modest rise in osteoporosis: roughly 4% of users versus 3% of non-users. The likely cause is not the drug itself but the rapid weight and muscle loss that comes with it, which is preventable.
In the first randomised human trial to look at it, semaglutide slowed several markers of biological ageing by around 9%. The likely reason: less inflammation and less fat around the organs.
AstraZeneca's once-daily pill, elecoglipron, helped people with type 2 diabetes lose about 10.5% of their body weight in six months, with no injection required. The results were published in The Lancet.
More than 12,000 doctors and researchers met in New Orleans for the American Diabetes Association's 2026 sessions. The theme this year was a quiet shift: these drugs are no longer judged only by the scale.
Novo Nordisk's CagriSema, which combines semaglutide with a second appetite hormone, delivered about 14% weight loss in its REIMAGINE trials. Good numbers, but analysts felt they looked modest next to the competition.
We read the journals and the trial readouts so you don't have to, then send one calm summary on Sunday mornings. Unsubscribe in one click.
